Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 35Lymphoma, Large B-Cell, Diffuse 22Sarcoma 19Lymphoma 19Carcinoma, Hepatocellular 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Non-Hodgkin 9Hodgkin Disease 9Multiple Myeloma 8Leukemia 8Neuroblastoma 6Liver Neoplasms 6Lymphoma, Follicular 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Mantle-Cell 4Triple Negative Breast Neoplasms 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neoplasms, Plasma Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Liposarcoma 3Leiomyosarcoma 3Chondrosarcoma 3Burkitt Lymphoma 3Wilms Tumor 2Rhabdomyosarcoma 2

Interventions

raltitrexed 1lobaplatin 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Liver, Cancer of, Primary Resectable × Doxorubicin × Clear all
NCT05701436 2023-03-02

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Zhujiang Hospital

Phase 3 Unknown
144 enrolled

Liver, Cancer of, Primary Resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡